Speculation is rife about Abhishek Nayar's potential return to Kolkata Knight Riders after Varun Chakravarthy's cryptic Instagram post. Following his departure from the BCCI, fans are linking ...

Maître d’Hôtel and Walt Disney Legacy Award Winner Israel Perez showcases the current Victoria & Albert’s seasonal menu The Victoria & Albert’s menu shifts seasonally, so returning guests always get a ...

The reversal from the Advisory Committee on Immunization Practices (ACIP) is a potential boost for GSK and Pfizer. Both companies saw sales of their RSV vaccines for adults tumble last year after ...

Dr Chris Boshoff, Pfizer's Chief Scientific Officer, confirmed in statement on April 14: 'While we are disappointed to discontinue the development of danuglipron, we remain committed to ...

Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug ...

Disgraced Kingston City councillor Jane Agirtan has lashed out at her critics after being stood down for allegedly doxxing a lawyer, taking to social media to share a heated rant. Jane Agirtan was ...

Pfizer said it will stop developing the drug, called danuglipron, as a result Other alternatives to injectable obesity drugs are in development TUESDAY, April 15, 2025 (HealthDay News) — Pfizer ...

Pfizer opens new tab on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury which resolved ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...

We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks on Jim Cramer’s radar.

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant. The company said Monday the stoppage comes after it ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist ...